ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Platinum Compounds

Also written as “QLS5132; Platinum; Bevacizumab”, “HS-10502 + Platinum + Bevacizumab” and “Platinum”.

Its studies are mostly in Stomach Neoplasms · Ovarian Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Head and Neck Neoplasms, led by 5 companies.

Drug pagePlatinum Compounds: every studyMany companies study it; this page follows only the 5 they lead. All 26 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jun 24, 20165 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only10 open or runningphase 1since Jun 24, 2016Jun 24, 2016none ahead
Eli Lilly10 open or runningphase 2since Jun 1, 2005Jun 1, 2005none ahead
Hansoh Pharmaceutical Groupits history only11 open or runningphase 1since Jan 7, 2025Jan 7, 2025none ahead
Merck KGaA, Darmstadt, Germanyits history only10 open or runningphase 3since Jul 19, 2005Jul 19, 2005none ahead
Qilu Pharmaceuticalits history only11 open or runningphase 2since Mar 1, 2026Mar 1, 2026Apr 2027phase 2 · NCT07453394

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 1, 2005First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT00112346 · 120 enrolled · United States, Canada

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Eli Lilly leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00112346Carcinoma, Non-Small-Cell Lung · United States, Canada2CompletedDec 2006120

How it is read

Names in the registry

  • “QLS5132; Platinum; Bevacizumab”, 1 entry
  • “HS-10502 + Platinum + Bevacizumab”, 1 entry
  • “Platinum”, 1 entry
  • “Cetuximab + platinum + gemcitabine”, 1 entry
  • “Platinum + Gemcitabine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.